We have collected information about Delivery For Pulmonary Arterial Hypertension Pah for you. Follow the links to find out details on Delivery For Pulmonary Arterial Hypertension Pah.
https://clinicaltrials.gov/ct2/show/NCT01321073
Mar 23, 2011 · DelIVery for Pulmonary Arterial Hypertension (PAH) (DelIVery) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
https://trials.phassociation.org/trials/NCT01321073
DelIVery for Pulmonary Arterial Hypertension (PAH) Study Purpose The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver Remodulin® (treprostinil) Injection.
https://clinicaltrials.gov/ct2/show/results/NCT01321073
DelIVery for Pulmonary Arterial Hypertension (PAH) (DelIVery) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
https://journals.sagepub.com/doi/full/10.1177/2045894019878615
The DelIVery for Pulmonary Arterial Hypertension (PAH) clinical trial was a multi-center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system (IDS) consisting of a pump and a catheter for intravenous (IV) treprostinil.Author: Mardi Gomberg-Maitland, Robert C Bourge, Shelley M Shapiro, James H Tarver, Dianne L Zwicke, Jeremy ...
https://www.tandfonline.com/doi/abs/10.1080/17425247.2020.1729119
(2020). Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. Expert Opinion on Drug Delivery: Vol. 17, No. 4, pp. 439-461.
https://www.acc.org/latest-in-cardiology/articles/2017/01/18/07/36/implantable-intravenous-delivery-system-for-treprostinil-in-patients-with-pulmonary-arterial
Jan 18, 2017 · Current guidelines in the United States and Europe recommend treatment with parenteral prostanoids for severe or rapidly progressing pulmonary arterial hypertension (PAH). 2-4 However, risks and complexities associated with the current intravenous (IV) and subcutaneous (SC) delivery systems limit the acceptance of parenteral therapy. IV delivery via an indwelling central venous catheter …
Searching for Delivery For Pulmonary Arterial Hypertension Pah?
You can just click the links above. The data is collected for you.
